Inogen, Inc.

DB:6IO Stock Report

Market Cap: €195.3m

Inogen Management

Management criteria checks 0/4

Inogen's CEO is Kevin R. Smith, appointed in Nov 2023, has a tenure of 1.08 years. total yearly compensation is $2.45M, comprised of 4.4% salary and 95.6% bonuses, including company stock and options. directly owns 0.061% of the company’s shares, worth €119.31K. The average tenure of the management team and the board of directors is 0.9 years and 2.8 years respectively.

Key information

Kevin R. Smith

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage4.4%
CEO tenure1.1yrs
CEO ownership0.06%
Management average tenureless than a year
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin R. Smith's remuneration changed compared to Inogen's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$53m

Jun 30 2024n/an/a

-US$92m

Mar 31 2024n/an/a

-US$97m

Dec 31 2023US$2mUS$108k

-US$102m

Compensation vs Market: Kevin R.'s total compensation ($USD2.45M) is above average for companies of similar size in the German market ($USD841.30K).

Compensation vs Earnings: Insufficient data to compare Kevin R.'s compensation with company performance.

CEO

Kevin R. Smith (53 yo)

1.1yrs

Tenure

US$2,448,754

Compensation

Mr. Kevin R. M. Smith serves as President, Chief Executive Officer and Director at Inogen Inc. since November 13, 2023. He served as Director at OncoSec Medical Incorporated since February 7, 2020 until Ju...

Leadership Team

NamePositionTenureCompensationOwnership
Kevin R. Smith
President1.1yrsUS$2.45m0.061%
€ 119.3k
Michael Bourque
Executive VPless than a yearno datano data
Philip Corrin
Senior Vice President of Operations & Supply Chain1.8yrsno datano data
Kevin Smith
General Counsel & Executive VP of Business Developmentless than a yearno datano data
Jennifer Boyer
Executive VP & Chief Human Resources Officer2.6yrsno datano data
Grgoire Ramade
Executive VP & Chief Commercial Officerless than a yearno datano data
Krishna Jhaveri
Chief Medical Officerless than a yearno datano data
Paul Andreassi
Senior Vice President of Quality & Regulatory Affairsless than a yearno datano data
Adrien Mithalal
Senior Vice President of Research & Developmentless than a yearno datano data

0.9yrs

Average Tenure

54yo

Average Age

Experienced Management: 6IO's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Kevin R. Smith
President1.1yrsUS$2.45m0.061%
€ 119.3k
Richard Casaburi
Member of Advisory Boardno datano datano data
Jeffrey Kupperman
Member of Advisory Boardno datano datano data
Paul Selecky
Member of Advisory Boardno datano datano data
Mary Ladone
Independent Director2.8yrsUS$242.50k0.10%
€ 200.1k
Kevin King
Independent Director2.8yrsUS$250.00k0.10%
€ 200.1k
Neil MacIntyre
Member of Advisory Boardno datano datano data
Elizabeth Mora
Independent Board Chairperson3.6yrsUS$315.00k0.11%
€ 218.9k
Robert Chatburn
Member of Advisory Boardno datano datano data
Thomas West
Independent Director1.7yrsUS$266.24k0.079%
€ 154.2k
Heather Rider
Independent Director10.3yrsUS$242.50k0.16%
€ 309.2k
Glenn Boehnlein
Independent Director2.8yrsUS$250.00k0.10%
€ 200.1k

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: 6IO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 00:02
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inogen, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert MarcusJ.P. Morgan
Matthew MishanKeyBanc Capital Markets Inc.
Jeffrey CohenLadenburg Thalmann & Company